C4.4A as a candidate marker in the diagnosis of colorectal cancer

C4.4A is a member of the Ly-6 family with restricted expression in non-transformed tissues. C4.4A expression in human cancer has rarely been evaluated. Thus, it became important to explore C4.4A protein expression in human tumour tissue to obtain an estimate on the frequency of expression and the correlation with tumour progression, the study focusing on colorectal cancer. The analysis of C4.4A in human tumour lines by western blot and immunoprecipitation using polyclonal rabbit antibodies that recognize different C4.4A epitopes revealed C4.4A oligomer and heavily glycosylated C4.4A isoform expression that, in some instances, inhibited antibody binding and interaction with the C4.4A ligand galectin-3. In addition, tumour cell lines released C4.4A by vesicle shedding and proteolytic cleavage. C4.4A was expressed in over 80% of primary colorectal cancer and liver metastasis with negligible antibody binding and interaction with the C4.4A ligand galectin-3. In addition, tumour cell lines released C4.4A by vesicle shedding and proteolytic cleavage. C4.4A was expressed in over 80% of primary colorectal cancer and liver metastasis with negligible expression in adjacent colonic mucosa, inflamed colonic tissue and liver. This compares well with Epcam and CO-029 expression in over 90% of colorectal cancer. C4.4A expression was only observed in about 50% of pancreatic cancer and renal cell carcinoma. By de novo expression in colonic cancer tissue, we consider C4.4A as a candidate diagnostic marker in colorectal cancer, which possibly can be detected in body fluids.

Keywords: C4.4A; galectin-3; colorectal cancer; glycosylation; antigen shedding

C4.4A is a highly glycosylated glycosylphosphatidylinositol (GPI)-anchored protein with 30% homology to the urokinase receptor (uPAR) (Rösel et al., 1998). C4.4A, also described as Ly6/PLAUR domain containing 3, and uPAR belong to the Ly-6 family, characterised by repetitive cysteine residues which allow a typical ‘three finger’ folding via disulphide bridges (Tsetlin, 1999). While uPAR has three cysteine containing domains, C4.4A has two and the third domain is devoid of cysteines (Rösel et al., 1998). Most other members of the Ly-6 family have only one domain (Ploug and Ellis, 1994).

The C4.4A protein was first identified in a highly metastasizing rat pancreatic adenocarcinoma line (Matzku et al., 1989). In the rat, C4.4A (rC4.4A) is strongly upregulated during implantation of the blastocyst and is highly expressed in the placenta. In the adult, expression is restricted mostly to stratified epithelia of the skin and squamous epithelia of the upper gastrointestinal tract (Claas et al., 1996). At the mRNA level, a very similar expression profile of human (h) C4.4A was seen (Smith et al., 2001; Würfel et al., 2001). Recently, an antibody against hC4.4A and mouse (m) C4.4A was described (Hansen et al., 2004). With this antibody, expression of hC4.4A in placenta and skin was confirmed. In addition, mC4.4A expression was found to become upregulated in migrating keratinocytes during wound healing. In urothelium, too, C4.4A was described as an inducible wound response gene (Smith et al., 2001).

Although C4.4A expression is rather restricted in non-transformed tissues, C4.4A expression has been observed in several tumour entities. hC4.4A mRNA was detected in cancer cell lines of different origin including melanoma, breast, bladder and renal cell carcinoma (RCC) as well as in tumour tissues of malignant melanoma, breast cancer, lung carcinoma and lung tumour-derived metastases, and primary and metastatic transitional cell carcinoma of urothelial cell origin (Seiter et al., 2001; Smith et al., 2001; Würfel et al., 2001; Fletcher et al., 2003). Notably, and in line with the suggestion by Smith et al. (2001) that C4.4A accounts for an inducible wound response gene in urothelial cells, we observed inducibility of the C4.4A gene (gene symbol: LYPD3) in malignant melanoma (Seiter et al., 2001).

To further pursue the question of C4.4A as a potential tumour marker, we generated hC4.4A-specific antibodies to characterize the molecule as expressed under physiological conditions and in tumour tissue. We provide evidence for differences in C4.4A glycosylation, oligomer status and associated proteins. We also show that C4.4A is released from tumour cells. Taking the restricted expression in non-transformed tissue and high-level expression in primary colorectal cancer and liver metastasis, C4.4A might well be suited as a diagnostic colorectal cancer marker.

**Keywords:** C4.4A; galectin-3; colorectal cancer; glycosylation; antigen shedding
MATERIALS AND METHODS

Tissues and tumour lines

Colorectal carcinoma, normal colorectal and colitis ulcerosa tissue, liver metastasis of colorectal cancer and normal liver were collected during surgery and snap-frozen in liquid nitrogen. The mean age of patients with colorectal cancer (72 male and 25 female) was 64 and ranged from 38 to 90 years. A collection of snap-frozen tissues from normal kidney and RCC as well as from normal pancreatic gland, chronic pancreatitis and pancreatic cancer has recently been described (Gesierich et al, 2005; Devitt et al, 2006). The analysis of human healthy skin has been performed with paraffin-embedded biopsy specimens, taken for routine histopathology. Informed consent for tissue collection was obtained from each patient and tissue collection was approved by the University Ethics Review Board. The rat cell lines BSp73ASML (ASML) (Zöller et al, 1978), Progressor (Reisser et al, 1993) and 804G (Izumi et al, 1981) were grown in RPMI medium supplemented with 10% FCS. The embryonic kidney cell line HEK-293 was grown in Iscove’s medium supplemented with 10% FCS. The pancreatic adenocarcinoma lines BxPC3, Capan1, Capan2, Colo357, MiaPaca2, Panc1, Panc89 and 8.18 were maintained in RPMI 1640, supplemented with 10% FCS and 10 mM sodium pyruvate. The colorectal cancer lines Colo205, Colo320, Colo320DM, HT29, Lovo, SW480, SW707, SW948 and WIDR were maintained in RPMI 1640 and supplemented with 10% FCS. The origin of all these lines and the original depositors have recently been summarized (Gesierich et al, 2005). The prostate cancer cell lines LNCaP, PC-3 and DU145 were grown in RPMI 1640 and supplemented with 10% FCS. The breast cancer cell lines MCF-7, MELN, HCC, MDA-MB4361, BT47D were grown in DMEM with 10% FCS. The HaCaT cell line (Boukamp et al, 1988) was grown in DMEM with 10% FCS. All lines grew adherent and, when confluent, were detached with trypsin for subculture. For the evaluation of activation-dependent expression of C4.4A, tumour lines were starved overnight in RPMI 1640 medium not containing foetal bovine serum. Thereafter they were cultured for 24 h in medium containing 10% AB0 serum that was or was not heat-inactivated for 30 min at 56°C (Seiter et al, 2001).

Cloning of expression constructs and transient transfection of cells

A hC4.4A expression construct was generated by amplification of the hC4.4A coding sequence (Würfel et al, 2001) by PCR and cloning in the pCDNA3.1 vector (Invitrogen, Karlsruhe, Germany). HEK-293 were transiently transfected using the Polyfect transfection reagent (Qiagen, Hilden, Germany) as described by the manufacturer.

Antibodies

The following monoclonal and polyclonal antibodies were used: C4.4 (mouse anti-rat C4.4A) (Matzku et al, 1989); CO-029 (anti-human CO-029) (Sela et al, 1989); HEA125 (anti-human EpCAM) (Momburg et al, 1987); anti-human uPAR (American Diagnostics, New York, NY, USA); rabbit anti-galectin-3 (Santa Cruz, Santa Cruz, CA, USA); biotin-conjugated anti-rabbit (Jackson Immuno Research, West Grove, PA, USA); and anti-mouse HRP (horse-radish peroxidase), anti-rabbit HRP, streptavidin-HRP and anti-rabbit-phycocerythin (PE) (all Dianova, Hamburg, Germany). Anti-hC4.4A polyclonal antibodies were raised in rabbits immunised with peptides QTTPRQGVEHEASRDEEPRLTGGAAG and LTSRALDPGNEASYPPNGV coupled to keyhole limpet hemocyanin (KLH). Antibodies were purified by passage of the antisera over a Sepharose 4B column that had been coupled to the peptides according to the manufacturer’s protocol (Amersham Biosciences Europe GmbH, Freiburg, Germany).

Immunohistochemistry

Formalin-fixed, paraffin-embedded tissues were deparaffinised by two 5 min washes in xylene, then rehydrated through successive graded ethanol solutions and washed for 5 min in PBS. Antigen retrieval was achieved by immersing the slides in 0.01 m EDTA and boiling for 10 min in a water bath. Frozen sections were fixed 5 min in methanol/acetic (1 : 1). Endogenous hydrogen peroxidase activity was quenched by treating the slides in 3% hydrogen peroxidase/PBS for 10 min followed by two washes in PBS. The tissue was blocked in 10% BSA/PBS for 1 h. To avoid background staining due to the high content of mucus in colon and colorectal cancer tissue, slides were, in addition, pre-incubated for 30 min with 2% serum corresponding to the species of the secondary antibody before the addition of primary antibodies, which have been used at half the concentration applied for staining of non-colorectal tissue. Following three washes in PBS, the tissue sections were incubated with biotin-conjugated secondary antibody (Jackson ImmunoResearch) (5 µg ml⁻¹, 30 min) and alkaline phosphatase-conjugated avidin–biotin complex (Vector Laboratories, Grunberg, Germany) solutions (5 min). Tissue sections were counterstained with Mayer’s haematoxylin. Staining was assessed semiquantitatively by two independent observers according to the following score: no stained cells: –; weak staining or staining of less than 25% of cells: ± /0.5; moderate staining or staining of less than 50% of cells: + /1; moderate to strong staining of mostly >50% of cells: ++ /2; strong staining of >75% of cells: +++ /3. Tissues were considered as positive when both observers scored the tissue section as + /1. As far as the judgement of the two observers differed, new sections were stained and re-evaluated. These tissues were only considered as positive when both observers judged the repeated staining with + /1. As far as the judgement of both observers differed again, the tissue sample was not included in the final evaluation.

FACS analysis

Flow cytometry followed routine procedures using 1–3×10⁶ tumour cells per sample. Trypsinized cells were allowed to recover for 2 h at 37°C in RPMI 1640 with 10% FCS. The primary antibody was used at a concentration of 5 µg ml⁻¹ and was replaced by normal rabbit IgG in the negative control. The secondary antibody was PE- or APC-labelled. Samples were analysed using an FACS Calibur and the Cell Quest Program (Becton Dickinson, Heidelberg, Germany).

Immunoprecipitation

Cells (1×10⁶) were surface-biotinylated with 1 mg ml⁻¹ biotin-X-NHS WS (Calbiochem, San Diego, CA, USA) in HEPES puffer (25 mM HEPES, 150 mM NaCl, 5 mM MgCl₂ (pH 7.4)) for 30 min at room temperature and lysed for 1 h at 4°C in 4 ml HEPES puffer with 1% Triton X-100 and a protease inhibitor cocktail (Roche Diagnostics GmbH, Mannheim, Germany). After centrifugation for 30 min at 20000 g, lysates (1 ml) were precleared by incubation with 1/10 volume protein G-Sepharose for 2 h at 4°C. Pre-cleared lysates were incubated 3 h at 4°C with 1 µg of antibody or control IgG. Immune complexes were washed four times with lysis buffer and precipitated proteins were analyzed by SDS–PAGE, followed by western blot (WB).

Western blot

Proteins were resolved in 12% SDS–PAGE under non-reducing or reducing conditions and the proteins were transferred to PVDF membrane at 30 V overnight. After blocking (5% fat-free milk powder in PBS), membranes were incubated with streptavidin-HRP or with the indicated primary antibodies, followed by
HRP-coupled secondary antibodies. Blots were developed with the enhanced chemiluminescence detection system (Amersham Biosciences Europe GmbH).

**Galectin-3 pull-down**

Glutathione-S-transferase (GST)-galectin-3 was purified as described previously (Paret et al, 2005). For the GST pull-down, GST-galectin-3 fusion protein and GST, respectively, were immobilized on glutathione (GSH)-sepharose beads and allowed to interact for 2 h at 4°C with whole-cell lysate from the indicated cell lines. Following binding, GSH-sepharose beads were washed extensively with PBS containing 1% Triton X-100 and proteins were released by addition of 1% SDS. Released proteins were analysed by SDS–PAGE followed by WB. Where indicated, released proteins were deglycosylated before loading on SDS–PAGE gel.

**Detection of released C4.4A**

Microvesicles were prepared by multi-step centrifugation. Cell culture supernatants were centrifuged two times at 800 g, followed by centrifugation at 1600 and 6000 g. Finally, microvesicles were precipitated by ultracentrifugation at 200 000 g and resuspended in PBS. Were indicated, microvesicles were subjected to deglycosylation before further analysis. Phase separation of C4.4A in Triton X-114 was performed as follows. After multi-step centrifugation (800, 1600 and 6000 g), cell culture supernatant was immunoprecipitated with C4.4 antibody. Immunoprecipitated C4.4A was eluted from the protein G-antibody complex using 100 mM glycine at pH 2. After neutralisation, the solution was adjusted to 2% Triton X-114 and incubated for 1 h at 4°C. Samples were cleared by centrifugation at 20 000 g for 10 min at 4°C. The supernatant was incubated for 5 min at 37°C. The detergent-rich and aqueous phases were separated by centrifugation for 5 min at 20 000 g at room temperature. Detergent-rich and aqueous phases were adjusted to identical volumes using PBS and analyzed for the presence of C4.4A by SDS–PAGE followed by WB.

**Trypsin digestion**

Recombinant rC4.4A (rrC4.4A) carrying a myc tag at the C terminus (Paret et al, 2005) was digested for 2 h at 37°C with trypsin at the indicated concentrations.

**Deglycosylation**

*In vivo* deglycosylation was performed by adding tunicamycin (SIGMA, Steinheim, Germany) at 5 μg ml⁻¹ to the cell culture medium overnight. For *in vitro* deglycosylation, cell lysates, immunoprecipitates, microvesicles or precipitates after pull-down were incubated for 16 h at 37°C with N-glycosidase F (20 U ml⁻¹; ROCHE, Mannheim, Germany) and/or O-glycosidase (2.5 U 100 ml⁻¹; ROCHE) and/or neuraminidase (0.05 U ml⁻¹; SIGMA) in PBS containing 1% Triton X-100 before analysis by SDS–PAGE.

**Statistics**

According to the specific question, association between quantitative and ordered variables was quantified by Spearman’s rank correlation; the Jonckheere–Terpstra test for trend was used to investigate a trend in proportions; and the Wilcoxon rank sum test was used for two-group comparisons of quantitative variables. The signed rank test was used to compare paired quantitative observations. All tests were performed two-sided at the 0.05 level. Ninety-five percent confidence intervals were calculated for mean observations. All tests were performed two-sided at the 0.05 level. For the GST pull-down, all calculations were performed using SAS version 9.1 (SAS Institute Inc. Corp, NC, USA).

**RESULTS**

**Characterisation of rabbit polyclonal antibodies against hC4.4A peptides**

Antibodies were generated by vaccination of rabbits with KLH-coupled hC4.4A peptides located at the C terminus (anti-hC4.4A-C) and N terminus (anti-hC4.4A-N) (Figure 1A). The hC4.4A peptides were coupled to sepharose, and C4.4A-specific antibodies were isolated from the antiserum by passage over the peptide-coupled sepharose. The specificity of the antibodies was further verified by transfecting HEK-293 cells with hC4.4A cDNA. hC4.4A expression was analysed by WB. Only HEK-293 cells transfected with the hC4.4A cDNA showed a band of the expected size, whereas no reactivity was observed with lysates of HEK-293 cells transfected with the empty vector (Figure 1B). The anti-hC4.4A-C antibody stained paraffin-embedded specimens of healthy human skin, where expression of hC4.4A was restricted to the stratum granulosum. No staining was seen in the sections using a control IgG (Figure 1C). Both antibodies recognised the hC4.4A protein in WB in the immortalized keratinocyte line HaCaT (Figure 1D), which had been shown before by *in situ* hybridization to be C4.4A-positive (Würfel et al, 2001).

**Expression of hC4.4A in cancer lines**

C4.4A expression on cancer cell lines was revealed by flow cytometry using the anti-hC4.4A-C antibody. Five breast, three prostate, five of eight pancreas and five of nine colorectal cancer lines were positive for hC4.4A (Table 1). Because C4.4A, similar to uPAR expression (Mazumdar et al, 2001), has been described to become upregulated or induced by, for example, heat-labile serum factors (Seiter et al, 2001), expression of C4.4A on colorectal cancer lines was re-evaluated after cells had been cultured for 24 h in the presence of fresh AB0 serum. Expression in the C4.4A-positive lines mostly remained unaltered, but C4.4A expression was induced by heat-labile serum factors in colorectal cancer lines that in the resting state did not or very weakly express C4.4A (Table 1 and Figure 2A). C4.4A expression was confirmed by immunoprecipitation of biotinylated lysates (Figure 2B, left), which revealed significant differences in the molecular weight of hC4.4A. The band indicated with arrow 3 corresponds in the molecular weight to the monomeric form of hC4.4A. Changes in the molecular weight of this band between different cell lines are probably due to differences in the glycosylation state. After *in vivo* deglycosylation with tunicamycin, an inhibitor of N-glycosylation, a band of about 50 kDa is detectable by WB analysis in MCF-7 and BxPC3 cell lysates using the anti-hC4.4A-N antibody. A size reduction was also observed after *in vitro* deglycosylation with N-glycosidase F of immunoprecipitated hC4.4A from the MCF-7 cell line (Figure 2E). The expected size of the protein as calculated from the amino-acid composition is 32 kDa. Thus, O-glycosylations likely account for the difference to the expected size. In the presence of O-glycosidase alone, protein size was unchanged (data not shown), indicating that O-glycosylations carry sialic acid modifications. Indeed, in the presence of neuraminidase and O-glycosidase, the protein size was reduced to a broad band of 35–40 kDa (Figure 2E).
Notably, the fully glycosylated C4.4A isoform as expressed in MCF-7 and BxPC3 cells is not recognized by both antibodies in WB, as demonstrated for hC4.4A-N (Figure 2D), but both antibodies reacted well with hC4.4A on the HaCaT cell line (Figure 1D). Because the hC4.4A-N antibody did react with the tumour line lysates after N-deglycosylation, it is likely that C4.4A glycosylation differs in HaCaT cells and the tested tumour lines, where in the latter the binding sites may be masked by glycosylation. Flow cytometry analysis of C4.4A expression in colorectal cancer lines was also repeated after O- and N-deglycosylation. In most lines, staining intensity was at least slightly increased after O- or N-deglycosylation. Staining intensity was most strongly increased after N-deglycosylation of Colo205 and after O-deglycosylation of Lovo (data not shown).

We previously described that rat C4.4A interacts with galectin-3 (Paret et al, 2005). Because binding depends on the carbohydrate residues of C4.4A, we wondered if all glycosylation forms of C4.4A bind galectin-3. In fact, only 5 of 7 human cancer cell lines express a C4.4A isoform, which allows galectin-3 binding (Figure 2F).

Immunoprecipitation of biotinylated human cancer cells with anti-hC4.4A-N uncovered additional features that differed between the individual lines. The higher molecular weight band, seen with MCF-7, Colo357 and, albeit weakly, with DU145 and LNCaP cell lysates (Figure 2A, arrow 1) possibly is a C4.4A oligomer, because it disappears after reduction with 2-mercaptoethanol (2-ME) as demonstrated for MCF-7 and Colo357 (Figure 2B). Moreover, in the presence of 2-ME, the monomeric form of Colo357 and MCF-7 runs at a slightly higher molecular weight. This could be due to the reduction of the disulphide bridges contained in the two Ly-6 domains and the loss of the three-dimensional folding. Interestingly, the putative C4.4A oligomer was detected only in cancer cell lines, which according to the flow cytometry analysis displayed high hC4.4A expression. A band of about 100 kDa (Figure 2A and B, arrow 2) could represent a highly glycosylated form of hC4.4A or an interacting protein. The latter is more likely, because the band is still visible after deglycosylation (Figure 2D). Two additional co-immunoprecipitating proteins of about 38 and 25 kDa were detected in the precipitate of the HaCaT cell line.

| Table 1 hC4.4A expression in human cancer cell lines (flow cytometry) |
|---------------------------------------------------------------|
| **C4.4A expression** |
| **Pancreatic cancer** | **Intensity** | **Colorectal cancer** | **Intensity** | **Intensity** | **Intensity** | **Breast cancer** | **Intensity** | **Prostate cancer** | **Intensity** |
| Colo357 | +++ | SW480 | + | + | MCF-7 | +++ | LNCaP | +++ |
| Capan2 | ++ | Colo205 | + | + | MELN | +++ | Du145 | +++ |
| Panc89 | ++ | HT29 | – | + | HCC1937 | ++ | PC3 | + |
| BxPC3 | + | WDR | – | + | BT47D | + |
| MiaPaca2 | + | Colo320 | – | + | MDA-MB436 | + |
| Panc1 | – | Colo320DM | + | + | |
| B18 | – | SW707 | + | + | |
| Capan1 | – | SW948 | ++ | ++ | Lovo | ++ | |

*Flow cytometry data were analysed according to the increase in the mean fluorescence intensity as compared to the negative control (normal rabbit IgG plus anti-rabbit IgG-PE): -- (negative), intensity 1.0- to 1.5-fold; + (distinct), intensity 1.5- to 4-fold; ++ (strong), intensity 4- to 10-fold; +++ (very strong), intensity >10-fold. **Cells were starved overnight and thereafter incubated for 24 h in RPMI 1640 containing 10% fresh AB0 serum.*
C4.4A in colorectal cancer
C. Paret et al

Figure 2  Expression of hC4.4A in cancer cell lines. (A) C4.4A expression was evaluated in colorectal cancer lines, which were cultured in heat-inactivated (grey area) or fresh ABO serum (black area). Overlays with the negative control (normal rabbit IgG anti-rabbit APC) are presented. (B) Biotinylated lysates of the indicated cell lines were immunoprecipitated using anti-hC4.4A-C. Immunoprecipitates were boiled, separated by SDS–PAGE and blotted with streptavidin-HRP. Depending on the cell line, several bands were recovered (indicated by arrows), which represent different C4.4A isoforms and/or associated proteins (see Results). (C) Biotinylated lysates of Colo357 and MCF-7 cells were immunoprecipitated using anti-hC4.4A-C, and immunoprecipitates were boiled in the presence of 2-ME before SDS–PAGE and blotting with streptavidin-HRP. The high molecular weight band of about 200 kDa was not recovered after 2-ME treatment. (D) Where indicated, MCF-7 cells were treated with tunicamycin (Tun). Lysates were separated by SDS–PAGE and blotted with anti-hC4.4A-N. The antibody recognizes only lysates from Tun-treated cells. (E) Lysates of MCF-7 cells were biotinylated and immunoprecipitated with the anti-hC4.4A-C antibody. Where indicated, immunoprecipitates were treated with N-glycosidase F (N-glycosid.) or with O-glycosidase (O-glycosid.) plus neuraminidase (NA) before SDS–PAGE separation and WB analysis with streptavidin-HRP. O-glycosidase plus NA treatment resulted in a size reduction of C4.4A from 75 to 35 kDa – 40 kDa. (F) Cell lysates of the indicated lines were incubated with GST-galectin-3 or GST. Bound proteins were eluted with 100 mM lactose. Eluted proteins were treated with N-glycosidase F before SDS–PAGE and blotting with anti-hC4.4A-N. C4.4A with a molecular weight of about 55 kDa was recovered in the precipitate of 5 out of 7 lines, but only after incubation with GST-galectin-3 and not after incubation with GST.

and albeit weakly in DU145 (35 kDa) and BxPC3 (25 kDa) cell lysates (arrow 4 and 5). Because cells were labelled with membrane impermeable biotin, these two interacting proteins are likely membrane-associated. Identification of these associating proteins that are absent or very weakly expressed in tumour lines is in progress. Taken together, human tumour cell lines frequently express highly glycosylated C4.4A, which obviously can prevent binding of the antibodies generated by peptide vaccination and can also interfere with the association of galectin-3 with C4.4A. High C4.4A expression can also lead to oligomer formation. The consequences of the glycosylation-prohibited associations as well as of oligomer formation on the function of C4.4A remain to be explored.

Expression of C4.4A and galectin-3 in colorectal, pancreatic and RCC

C4.4A expression was evaluated in frozen specimen of colorectal cancer, liver metastasis of colorectal cancer, pancreatic adenocarcinoma and RCC by immunohistochemistry. Normal colon and normal liver do not (98 and 97%, respectively) or very weakly (2 and 3%, respectively) express hC4.4A. Yet, >80% of colon cancer and >70% of liver metastasis show distinct to strong staining. Importantly, C4.4A expression was not induced in inflamed (colitis ulcerosa) tissue of the colon. While kidney and pancreatic gland tissue also did not or weakly express C4.4A, C4.4A expression was observed in 47% of RCC and 53% of pancreatic adenocarcinoma. However, C4.4A expression was also seen in 40% of chronic pancreatitis tissue (Table 2A). To validate the reliability of C4.4A as a tumour marker, particularly for colorectal cancer, expression of C4.4A was compared with galectin-3, EpCAM and CO-029 expression, that all three have been described to be upregulated in cancer tissue also did not or weakly express C4.4A, C4.4A expression was observed in 47% of RCC and 53% of pancreatic adenocarcinoma. However, C4.4A expression was also seen in 40% of chronic pancreatitis tissue (Table 2A). To validate the reliability of C4.4A as a tumour marker, particularly for colorectal cancer, expression of C4.4A was compared with galectin-3, EpCAM and CO-029 expression, that all three have been described to be upregulated in colorectal cancer (Sela et al, 1989; Armstrong and Eck, 2003; Nagy et al, 2003). In primary colorectal cancer, the sensitivity for C4.4A was 0.85 (95% CI: 0.73 – 0.84) and the specificity 1.00 (95% CI: 0.94 – 1.00). The sensitivity for galectin-3 was 0.79 (95% CI: 0.70 – 0.87) and the specificity 0.97 (95% CI: 0.91 – 0.99). The sensitivity for EpCAM was 0.94 (95% CI: 0.87 – 0.98) and the specificity 0.80 (95% CI: 0.71 – 0.87). The sensitivity for CO-029 was 0.98 (95% CI: 0.92 – 1.00) and the specificity 0.94 (95% CI: 0.86 – 0.98) (Kuhn et al, 2007). Thus, sensitivity of EpCAM was slightly (P = 0.08) and of CO-029 was significantly higher (P = 0.004) than for C4.4A. However, the specificity of EpCAM was significantly reduced compared with C4.4A (P = 0.002). The corresponding values for liver metastasis of colorectal cancer are C4.4A: 0.79 sensitivity (95% CI: 0.63 – 0.90), 1.00 specificity (95% CI: 0.90 – 100%); galectin-3: 0.83 sensitivity (95% CI: 0.70 – 0.91), 1.00 specificity (95% CI: 0.94 – 1.00); EpCAM: 0.93 sensitivity (95% CI: 0.83 – 0.98), 0.91 specificity (95% CI: 0.81 – 0.97); and CO-029: 0.94 sensitivity (95% CI: 0.85 – 0.99), 0.94 specificity (95% CI: 0.85 – 0.99) (Kuhn et al,
Accordingly, in liver metastasis of colorectal cancer, the sensitivity of EpCAM and CO-029 also was significantly higher than for C4.4A ($P = 0.04$ and 0.02, respectively). The specificity of EpCAM was slightly reduced compared with C4.4A.

There have been too few colitis ulcerosa tissues to warrant statistical analysis. It should, however, be mentioned that, distinct to C4.4A (Table 2A), galectin-3 expression was variable in colitis ulcerosa. Three out of six tissue samples showed no staining, two samples were weakly stained and one sample was distinctly stained (data not shown).

Staining of ductal cells of the pancreatic gland with anti-CO-029 had been observed in 50% and of pancreatic cancer tissue in 100% (Gesierich et al., 2005). EpCAM expression was not only seen in 87% of pancreatic adenocarcinoma, but also in 87% of the pancreatic gland. However, pancreatic gland tissue was not stained by anti-uPAR, a marker discriminating between chronic pancreatitis and pancreatic adenocarcinoma (Chen et al., 2007), whereas 67% of pancreatic adenocarcinoma were stained. The data correspond to sensitivity values of C4.4A: 0.53, galectin-3: 0.80, EpCAM: 0.87, CO-029: 1.00 and uPAR: 0.67. Accordingly, the sensitivity of galectin-3 ($P = 0.03$), EpCAM ($P = 0.005$) and CO-029 ($P < 0.0001$) was significantly higher than the sensitivity of C4.4A. However, the specificity of galectin-3 (0.75) was equal ($P = 1$), and the specificity of EpCAM (0.13) ($P = 0.0004$) and CO-029 (0.50) ($P = 0.02$) was significantly lower than that of C4.4A (1.00). Urokinase receptor also showed a sensitivity of 1.00.

Also, 38% of RCC sections, which differentially express uPA and uPAR (Bhuvahamurthy et al., 2005), were stained by anti-uPAR; kidney sections were not stained. Thus, uPAR and C4.4A showed a specificity value of 1.00. The sensitivity values of 0.57 for C4.4A and 0.38 for uPAR differed significantly ($P = 0.009$).

It should be kept in mind that we used suboptimal concentrations of all antibodies for the staining of colonic mucosa and colorectal cancer tissue to avoid unspecific staining. As we observed staining of colorectal cancer tissue with all four antibodies in 79–98%, it implies that irrespective of the possible underestimate particularly of EpCAM and galectin-3 expression in normal tissue, expression of these four molecules is significantly upregulated in colorectal cancer such that expression in primary colorectal cancer and that in liver metastasis differ at a highly significant level from expression in the corresponding normal tissue. For C4.4A expression, this also accounts for the comparison to inflamed tissue (Table 2A and B).

Finally, we want to point out, as exemplified in Figure 3, that C4.4A expression was restricted to the tumour cell membrane. Galectin-3 was predominantly expressed in the tumour cells, but not at the tumour cell membranes.

### Table 2 Expression of C4.4A in colorectal, pancreatic and renal cell carcinoma

#### (A) Comparison between tumour and non-transformed tissue

| Tissue                  | No. of samples | Negative (-) | Weak (+) | Distinct (+) C4.4A | Strong (+) | Very strong (+++) | P-value 1 |
|-------------------------|----------------|---------------|----------|---------------------|------------|-------------------|-----------|
| Colonic mucosa          | 61             | 98.4          | 1.6      | 0.0                 | 0.0        | 0.0               |           |
| Colitis ulcerosa        | 6              | 100.0         |          | 0.0                 | 0.0        | 0.0               |           |
| Colorectal carcinoma    | 55             | 7.3           | 7.3      | 23.6                | 32.7       | 29.1              | <0.0001   |
| Liver                   | 35             | 97.1          | 2.9      | 0.0                 | 0.0        | 0.0               |           |
| Liver metastasis        | 38             | 13.2          | 7.9      | 31.6                | 31.6       | 15.8              | <0.0001   |
| Pancreatic gland        | 8              | 62.5          | 37.5     | 0                   | 0          | 0                 |           |
| Chronic pancreatitis    | 10             | 40.0          | 20.0     | 10.0                | 20.0       | 10.0              | 0.01      |
| Pancreatic carcinoma    | 30             | 26.7          | 20.0     | 40.0                | 10.0       | 3.3               | 0.01      |
| Kidney                  | 10             | 70.0          | 30.0     | 0.0                 | 0.0        | 0.0               |           |
| Renal cell carcinoma    | 61             | 21.3          | 21.3     | 31.1                | 16.4       | 9.8               | NS        |

#### (B) Comparison between different tumour markers

| Marker                  | C4.4A         | Galectin-3  | EpCAM  | CO-029 | UPAR  |
|-------------------------|---------------|-------------|--------|--------|-------|
| Colorectal cancer       |               |             |        |        |       |
| No cancer tissue        | 55            | 100         | 100    | 93     |       |
| No control tissue       | 61            | 100         | 100    | 93     |       |
| Sensitivity             | 0.85          | 0.79 (NS)   | 0.94 (NS) | 0.98 (0.004) |       |
| Specificity             | 1.00          | 0.97 (NS)   | 0.80 (0.0002) | 0.94 (0.045) |       |
| Liver metastasis        |               |             |        |        |       |
| No cancer tissue        | 38            | 57          | 57     | 54     |       |
| No control tissue       | 35            | 57          | 57     | 54     |       |
| Sensitivity             | 0.79          | 0.83 (NS)   | 0.93 (0.04) | 0.94 (0.02) |       |
| Specificity             | 1.00          | 1.00 (NS)   | 0.91 (NS) | 0.94 (NS) |       |
| Pancreatic cancer       |               |             |        |        |       |
| No cancer tissue        | 30            | 30          | 30     | 30     | 30    |
| No control tissue       | 8             | 8           | 8      | 8      | 8     |
| Sensitivity             | 0.53          | 0.80 (0.003) | 0.87 (0.005) | 1.00 (0.0002) | 0.67 (NS) |
| Specificity             | 1.00          | 0.75 (NS)   | 0.13 (0.0004) | 0.50 (0.02) | 1.00 (NS) |
| Renal cell carcinoma    |               |             |        |        |       |
| No cancer tissue        | 61            |             |        |        | 61    |
| No control tissue       | 10            |             |        |        | 10    |
| Sensitivity             | 0.57          |             |        |        | 0.38 (0.009) |
| Specificity             | 1.00          |             |        |        | 1.00 (NS) |
Molecular Diagnostics

1152

+, ++ and +++ were considered as positive. Part of these analyses has already been described (Gesierich et al., 2005; Kuhn et al., 2007). Sample with a score of 0 or ± were considered negative; samples with a score of +, ++ and +++ were considered as positive. Part of these analyses has already been described (Gesierich et al., 2005; Kuhn et al., 2007). Sample with a score of 0 or ± were considered negative; samples with a score of +, ++ and +++ were considered as positive; sensitivity = true positive (true positive + false negative); specificity = true negative (true negative + false positive).

C4.4A % stained (mean staining intensity) & P-value<sup>a</sup> & Galectin-3 % stained (mean staining intensity) & P-value<sup>a</sup>

| Primary tumour staging | No. of samples | C4.4A % stained (mean staining intensity)<sup>b</sup> | P-value<sup>a</sup> | No. of samples | Galectin-3 % stained (mean staining intensity)<sup>b</sup> | P-value<sup>a</sup> |
|------------------------|----------------|----------------------------------|---------------------|----------------|----------------------------------|---------------------|
| T0–I                   | 4              | 100 (2.00)                       | NS                  | 6              | 100 (1.50)                       | NS                  |
| T2                     | 11             | 100 (2.50)                       |                     | 22             | 100 (1.75)                       |                     |
| T3                     | 25             | 84.0 (1.68)                      | 49                  | 91.8 (1.73)    |                                  |                     |
| T4                     | 15             | 100.0 (1.68)                     | 20                  | 95.0 (1.74)    |                                  |                     |
| Lymph node staging     |                |                                 |                     |                |                                  |                     |
| N0                     | 35             | 94.3 (1.51)                      | NS                  | 61             | 96.7 (1.66)                      | NS                  |
| N1                     | 12             | 91.7 (1.90)                      | 23                  | 100.0 (1.77)   |                                  |                     |
| N2                     | 8              | 87.5 (1.42)                      | 13                  | 76.9 (1.55)    |                                  |                     |
| Metastasis staging     |                |                                 |                     |                |                                  |                     |
| M0/mix                 | 43             | 93.0 (1.62)                      | NS                  | 74             | 95.6 (1.69)                      | NS                  |
| M1                     | 12             | 91.7 (1.85)                      | 23                  | 91.3 (1.81)    |                                  |                     |
| Primary tumour grading |                |                                 |                     |                |                                  |                     |
| G0/G1                  | 2              | 100.0 (2.20)                     | NS                  | 5              | 100.0 (1.83)                     | NS                  |
| G2                     | 44             | 90.9 (1.86)                      | 72                  | 94.4 (1.72)    |                                  |                     |
| G3/G4                  | 9              | 88.9 (1.83)                      | 20                  | 95.0 (1.74)    |                                  |                     |

D) Correlation to colorectal tumour grading and staging

C4.4A was also detected in the tumour stroma of some tissue samples. In colitis ulcerosa, galectin-3 expression was restricted to stromal cells (Figure 3).

Considering C4.4A expression in pancreatic cancer and RCC, the sensitivity values of 0.53 and 0.57 rather excluded C4.4A in these tumour entities as a diagnostic marker. Therefore, additional statistical analyses on a potential correlation between C4.4A and galectin-3 expression and clinical parameters of grading, staging and disease-free survival were performed only for colorectal cancer and liver metastases derived thereof. As could have been expected by the high frequency and the high level of C4.4A and galectin-3 expression in colorectal cancer, expression of both molecules did not become upregulated at a statistically significant level in dependence on tumour grading, the involvement of lymph nodes and distant organs. C4.4A and galectin-3 expression also did not significantly vary depending on tumour grading (Table 2C). Finally, C4.4A and galectin-3 expression did not correlate at a statistically significant level with the disease-free survival (Table 2D).

C4.4A is released in the supernatant of cancer cells lines

The C4.4A-related uPAR molecule mostly is shed without a GPI anchor (Ploug et al., 1992; Wilhelm et al., 1999), but uPAR fragments have also been described (Sidenius et al., 2000; Montuori et al., 2005; Beaufort et al., 2007); uPAR with an intact GPI anchor is also detected in shed membrane vesicles (Wilhelm et al., 1999). To analyse whether C4.4A is present in shed membrane vesicles, supernatant of two rat and five human tumour lines was subjected to multi-step centrifugation for elimination of cell debris followed by ultracentrifugation to collect membrane vesicles. The rat tumour lines were included because the rat, different from the human C4.4A-specific antibodies, has been shown to recognize C4.4A indendently of glycrosylation and, in addition, is well suited for immunoprecipitation (Matzku et al., 1989; Rösel et al., 1998). C4.4A was found in the vesicles containing pellet of all lines (Figure 4A). To see whether the GPI anchor is cleaved during C4.4A release, ASML supernatant was concentrated and
immunoprecipitated after cell debris elimination. The immunoprecipitate was subjected to Triton X-114 extraction. Triton X-114-containing solutions are homogenous at 4°C, but separate into detergent-rich and aqueous phases at 37°C. Glycosylphosphatidylinositol anchor containing C4.4A, probably vesicle-associated, partitioned into the detergent-rich phase (Figure 4B, left). However, the major part of released rC4.4A partitioned into the aqueous phase (Figure 4B, right), indicating GPI anchor hydrolysis and removal of the hydrophobic portion of the anchor. In the water-soluble fraction, an additional rC4.4A fragment of about 40 kDa was detected (Figure 4B), which could represent a proteolytic cleavage product of C4.4A. To support this hypothesis, rrC4.4A carrying a myc tag at the C terminus was digested with trypsin. Thereafter, the proteins were separated by SDS–PAGE and blotted with C4.4 and anti-myc. Trypsin-treated rrC4.4A revealed a 40 kDa protein, when blotted with C4.4. Only the undigested rrC4.4A was detected with the anti-myc antibody, indicating that the fragment represents the terminal part of C4.4A (Figure 4C). In fact, a protease-sensitive region between domains 2 and 3 of C4.4A has recently been described (Hansen et al., 2004). Thus, similar to uPAR, cancer cells release C4.4A with its GPI anchor in shed vesicles, as soluble, GPI anchor cleaved molecule and as fragments thereof.

**DISCUSSION**

The GPI-anchored C4.4A glycoprotein was first identified in a highly metastasizing rat pancreatic adenocarcinoma line (Matzku et al., 1989). The possible importance of the protein as tumour marker was indicated by the restricted expression in normal tissues (Rösel et al., 1998; Smith et al., 2001; Würfel et al., 2001) and upregulation of C4.4A mRNA in different tumours (Seiter et al., 2001; Smith et al., 2001; Fletcher et al., 2003). We here report C4.4A protein expression in several tumour lines and tumour tissues and provide first evidence suggestive for C4.4A as a possible serum marker for cancer diagnosis.

**Glycosylation, oligomer formation and interaction partners of C4.4A in human tumour lines**

Two polyclonal antibodies were raised against peptides localised at the C terminus and between domains 1 and 2, respectively, of
human C4.4A. The antibody against the C terminus stained the stratum granulosum of healthy human skin. A recently described polyclonal hC4.4A-specific antibody that cross-reacts with mC4.4A stained the suprabasal layer of the epidermis (Hansen et al., 2004). In the rat, C4.4A is strongly expressed by basal keratinocytes, which are in contact with the extracellular matrix, and staining decreases in suprabasal keratinocytes. These different staining profiles might be due to species differences. It is also possible that differences are due to the epitopes recognized by the different antibodies. Only for the generation of the monoclonal anti-rC4.4A antibody, mice were vaccinated with cell membranes (Matzku et al., 1989). This antibody obviously recognizes an epitope that does not become hidden by glycosylation (Rössel et al., 1998). Instead, a recent study proposed that an antibody (Hansen et al., 2004) and our peptide vaccination-derived antibodies did not stain basal keratinocytes. However, these antibodies stained HaCaT cells. Because glycosylation of C4.4A shows great variability and glycosylation of keratinocytes depends on the differentiation status of the cells. Because glycosylation of C4.4A shows great variability and glycosylation of keratinocytes depends on the differentiation status (Meul et al., 2003), it becomes likely that the restricted epidermal staining patterns by distinct anti-C4.4A antibodies are a consequence of C4.4A glycosylation that may hide the respective epitopes.

In fact, C4.4A carries N- and O-glycosylation sites, where the O-glycosylations are modified by sialic acid. Interestingly, while hC4.4A was detected by WB in HaCaT cell lysate, both antibodies did not react in WB with hC4.4A in cancer cell lines, but the hC4.4A-N antibody did so after deglycosylation. The finding suggests that C4.4A glycosylation differs between tumour cell lines and the immortalized keratinocyte line HaCaT, such that binding sites for anti-hC4.4A-N and probably anti-hC4.4A-C are frequently masked by sugar chains in tumour lines. Indeed, the peptide recognised by the anti-hC4.4A-N antibody has a potential N-glycosylation site at AA position 129 and the peptide recognised by the anti-hC4.4A-C antibody is near a potential O-glycosylation site (Hansen et al., 2004). We previously described that C4.4A interacts with galectin-3 (Paret et al., 2005), which is associated with colorectal cancer progression (Schoeppper et al., 1995; Nakamura et al., 1999; Endo et al., 2005). The interaction of galectin-3 with its cellular ligands depends on the glycosylation status of the interaction partner (Barondes et al., 1994). As a consequence of the glycosylated forms of hC4.4A as expressed on cancer cells did bind to galectin-3. Whether, indeed, differences in the C4.4A glycosylation state account for the distorted interaction with galectin-3 remain to be elucidated. However, altered glycosylation in cancer can play an important role in tumour cell adhesion and migration (Orntoft and Westergaard, 1999), as well as in extravasation via interaction with galectin-3 on endothelial cells (Lehr and Pienta, 1998; Glinsky et al., 2000; Krishnan et al., 2005). Two additional membrane proteins that associate with C4.4A in HaCaT cells, but very rarely in tumour cells as well as a high molecular weight protein, mainly detected in MCF-7 cells, remain to be identified.

C4.4A likely can form oligomers, which are not detected after 2-ME treatment and are reduced in size after deglycosylation. Because oligomers were only detected in cells, which according to flow cytometry analysis expressed C4.4A at a high level, the monomer/oligomer status may depend on the expression level. Furthermore, oligomers disappeared in the presence of β-mercaptoethanol. Thus, they are possibly formed via disulfide bridges. Alternatively, the native conformation of the molecule is required for oligomerisation. Expression level and oligomerisation of uPAR determine whether uPA elicits an adhesive or migratory response (Chiaradonna et al., 1999), high level uPAR expression contributes to tumorigenicity and invasiveness (Aguirre Ghiso et al., 1999), and oligomerisation of uPAR is required for vitronectin binding (Wei et al., 1994; Sidienius et al., 2002). Whether the expression level of C4.4A and oligomerisation also has functional consequences remains to be explored.

C4.4A as a candidate marker for the diagnosis of colorectal cancer

C4.4A is expressed at different levels in primary colorectal cancer as well as in liver metastasis in more than 80% of the patients with negligible expression in normal colonic mucosa and normal liver. Importantly, C4.4A expression was also observed in colorectal cancer lines. C4.4A expression was compared with the expression of EpCAM, galectin-3 and CO-029, which have been described as reliable markers in colorectal cancer (Sela et al., 1989; Armstrong and Eck, 2003; Nagy et al., 2003). With respect to sensitivity, EpCAM (liver metastases, only) and CO-029 were superior to C4.4A. However, with respect to specificity, C4.4A proved to be superior to EpCAM and CO-029. Notably, too, frequency and intensity of C4.4A expression apparently did not vary at a statistically significant level in dependence on tumour grading and staging, nor between primary tumours and metastasis. Therefore, one could argue that C4.4A expression is induced early during tumorigenesis and remains stable. However, our data do not allow to exclude upregulation during tumour progression. First, immunohistochemistry is a semi-quantitative method; second, we experienced that very high C4.4A expression can be accompanied by oligomerisation, which may prevent recognition by the available antibodies; third, the antibodies also do not bind to highly glycosylated C4.4A. The fact that we observed at the RNA level a clear upregulation of C4.4A expression at the tumour boundary and in metastatic tissue of malignant melanoma (Seiter et al., 2001) rather argues for C4.4A expression levels to be regulated also in tumour tissue, which possibly becomes hidden by modifications of the molecule that prevent recognition by the available antibodies. Nonetheless, the high frequency of C4.4A expression in colorectal cancer and liver metastasis makes the molecule a candidate marker in the diagnosis of colorectal cancer.

Despite the high frequency of C4.4A expression in primary tumours and liver metastases, C4.4A expression was noted only in 5 of 9 colorectal cancer lines. This feature is in line with the notion that C4.4A expression is strictly regulated (Seiter et al., 2001; Smith et al., 2001; Hansen et al., 2004), requires a C/EBPβ/junD or c-Jun complex for induction of transcription (Fries et al., 2007) and can also be induced in tumour lines by not yet defined heat-labile serum factors (Würfel et al., 2001). These stimuli will be present in vivo, but be missed in culture. In fact, de novo C4.4A expression was seen in colorectal cancer lines after starving and culturing in fresh serum.

We also evaluated C4.4A expression in pancreatic cancer tissue, which had been tested before for CO-029 expression (Giesierch et al., 2005). C4.4A expression was only seen in 53% of pancreatic cancer tissue. Though it was absent in normal pancreatic tissue, C4.4A was also expressed in 40% of chronic pancreatitis. Thus, for pancreatic adenocarcinoma, uPAR expression (Chen et al., 2007) may be a more reliable parameter than C4.4A expression. In RCC, the vast majority of which were clear cell carcinoma (Devitt et al., 2006), both C4.4A and uPAR (Bhuvaramurthy et al., 2005) expressions show low sensitivity. Still, C4.4A proved to be the more sensitive marker.

Finally, the finding that C4.4A is released by cancer cells may well become important for its potential use in colorectal cancer diagnosis. Different forms of released C4.4A were detected. Part of released C4.4A contains a GPI anchor and is likely vesicle-associated. Vesicle shedding can occur in different normal cells (Dainiak, 1991), but is strongly accelerated in cancer cells (Taylor and Black, 1986). Similar to uPAR (Ploug et al., 1992; Wilhelm et al., 1999), the majority of released C4.4A has no GPI anchor, possibly due to the activity of GPI-specific phospholipase D (Wilhelm et al., 1999). The supernatant of the ASML tumour line also contained a C4.4A fragment, which corresponds in size to a cleavage product of released C4.4A. The supernatant of the ASML tumour line also contained a C4.4A fragment, which corresponds in size to a cleavage product of released C4.4A.
compatible with C4.4A cleavage at a protease-sensitive  
region between the second and the third domain (Hansen et al., 2004).  
Interestingly, soluble uPAR and uPAR fragments are present in the  
blood of patients with different types of solid tumours, for example  
non-small cell lung cancer, breast, colorectal, prostate and ovarian  
cancer (Pappot et al., 1997; Stephens et al., 1997, 1999; Sier et al.,  
1998; Miyake et al., 1999), and are used as prognostic marker.  
Moreover, vesicles shed in vivo by breast carcinoma are similar to  
those shed in vitro by breast cancer cells and probably contribute  
to tumour markers present in the circulation of cancer patients  
(Dolo et al., 1995). Thus, it will be interesting to analyse the  
presence of hC4.4A in the serum and ascitic fluid of cancer patients  
and whether high enough amounts are present to allow for  
detection by a sensitive ELISA.

Besides C4.4A expression, we were particularly interested in  
 galectin-3 expression, which we had described to be an interaction  
partner for C4.4A (Paret et al., 2005). Galectin-3 is also expressed in  
over 70% of colorectal primary tumours and liver metastasis.  
Distinct to C4.4A, which is expressed exclusively by the epithelial  
tumour cells, galectin-3 can also be expressed by stromal cells and  
expression becomes upregulated in colitis ulcerosa tissue. Yet,  
the differences between expression levels in inflamed and malignant  
colorectal tissue remained significant. This is in line with several  
recent reports (Byrd and Bresalier, 2004) on high-level expression of  
galectin-3 in colorectal cancer. We did, however, not observe  
significant differences in the intensity of expression between low-  
and high-grade tumours and not in dependence on the disease-free  
survival, although a prolonged disease-free survival was accom-  
panied by a slight, statistically non-significant reduction in the  
mean intensity of expression (1.43) as compared to metastasis  
developing concomitantly with the primary tumour (mean intensity:  
1.73). Other studies revealed either similar results or  
reported upregulation of galectin-3 expression during tumour  
progression (Andre et al., 1999; Nakamura et al., 1999; Legendre  
et al., 2003, Nagy et al., 2003; Endo et al., 2005). Particularly one of  
the latter studies performed a highly sophisticated quantification of  
galectin-3 expression (Nagy et al., 2003). Taking into account that  
we observed a slightly lower galectin-3 expression in metastasis  
appearing after a prolonged disease-free survival, we would argue  
that probably galectin-3 expression becomes upregulated during  
tumour progression, but to a minor degree. Irrespective of this  
open question, and in line with several reports, galectin-3 still  
fulfils the criteria of a colorectal tumour marker with a sensitivity  
of 0.79 and 0.83 and a specificity of 0.97 and 1.00 in primary and  
metastatic tissue.

Our results suggest C4.4A as a candidate diagnostic marker for  
colorectal cancer. The possibility of C4.4A as tumour marker in  
body fluids remains to be explored. The advantage of C4.4A in  
colorectal cancer diagnosis relies not only on the high frequency and  
stable expression of expression, but particularly on the de novo expression  
of this molecule in colorectal cancer tissues or the strongly upregulated  
expression as for example in transitional cell cancer (Smith et al.,  
2001). In view of oligomerization and highly variable glycosylation of  
C4.4A, establishing a monoclonal antibody by vaccination with native,  
glycosylated C4.4A is desirable and may be mandatory for  
low-level detection of C4.4A in body fluids.

ACKNOWLEDGEMENTS

This work was supported by the Deutsche Krebshilfe (MZ, grant  
No 106859). We thank Dr M Ploug, Finsen Laboratory, Copenha-  
gen, for helpful suggestions and discussions during the preparation  
of the manuscript. We also thank Dr G Moldenhauer, German  
Cancer Research Center Heidelberg, for the HEA125 antibody; Dr  
D Herlyn, the Wistar Institute, Philadelphia, PA, USA, for CO-029;  
Christine Stumpf, Department of Immunogenetics, German Cancer  
Research Center, Heidelberg, for help with the staining of the  
paraffin-embedded skin section; and Jessica McAleer, Department of  
Tumor Progression and Immune Defense, German Cancer Research  
Center, Heidelberg, for help with editing.

REFERENCES

Aguirre Ghiso JA, Kovalski K, Ossowski L (1999) Tumor dormancy induced by  
downregulation of urokinase receptor in human carcinoma involves  
t integrin and MAPK signaling. J Cell Biol 147: 89 – 104

Andre S, Kojima S, Yamazaki N, Fink C, Kaltner H, Kayser K, Gabius HJ  
(1999) Galectins-1 and -3 and their ligands in tumor biology. Non-

uniform properties in cell-surface presentation and modulation of  
adhesion to matrix glycoproteins for various tumor cell lines, in  
biodistribution of free and liposome-bound galectins and in their  
expression as for example in transitional cell cancer (Smith  
et al., 2003; Endo et al., 2005). Particularly one of  
the latter studies performed a highly sophisticated quantification of  
the expression of  

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright: © 2007 Cancer Research UK

British Journal of Cancer (2007) 97(8), 1146 – 1156

© 2007 Cancer Research UK
Fries F, Nazareno J, Hess J, Claas A, Angel P, Zöller M (2007) CEBPB, JunD and c-Jun contribute to the transcriptional activation of the metastasis-associated C4.4A gene. Int J Cancer 120: 2135–2147

Gesierich S, Paret C, Hildebrand D, Weitz J, Zgraggen K, Schmitz-Winnenthal FH, Horejsi V, Yoshie O, Herlyn D, Ashkan LM, Zöller M (2005) Colocalization of the tetraspanins, CO-029 and CD151, with integrins in human pancreatic adenocarcinoma: impact on cell motility. Clin Cancer Res 11: 2840–2852

Glinsky VV, Hufnelt ME, Glinsky GV, Deutscher SL, Quinn TP (2000) Identification of the urokinase receptor (uPAR): identification and characterization of uPAR fragments in vitro and in vivo. FEBS Lett 475: 52–56

Hansen LV, Gardsvoll H, Nielsen BS, Lund LR, Dano K, Jensen ON, Ploug M (2004) Structural analysis and tissue localization of human C4.4A: a protein homologue of the urokinase receptor. Biochem J 380: 845–857

Izumi K, Hirao Y, Hopp L, Oyasa R (1981) In vitro induction of ornithine decarboxylase in urinary bladder carcinoma cells. Cancer Res 41: 405–409

Krishnan V, Bane SM, Kaope WD, Naresh KN, Kalraia RD (2005) Altered melanoma cell surface glycosylation mediates organ specific adhesion and metastasis via lectin receptors on the lung vascular endothelium. Clin Exp Metastasis 22: 11–24

Kuhn S, Koch M, Nübel T, Ladwein M, Antolovic D, Klingbeil P, Hildebrand D, Moldenhauer G, Langbein L, Franke WW, Weitz J, Zöller M (2007) Complex formation between CD44 variant isoforms with EpCAM and Claudin-7 in tetraspanin-enriched membrane micro-domains promotes colorectal cancer progression. Mol Cancer Res 5: 553–567

Legendre H, Decaestecker C, Nagy N, Hendizzes A, Schuring MP, Salmon I, Gabius HJ, Pector JC, Kiss R (2003) Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers. Mod Pathol 16: 491–504

Lerh J, Pieta K (1998) Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. J Natl Cancer Inst 90: 118–123

Matzku S, Wenzel A, Liu S, Zöller M (1989) Antigenic differences between metastatic and nonmetastatic Bsp73 rat tumor variants characterized by monoclonal antibodies. Cancer Res 49: 1294–1299

Mazumdar A, Adam L, Boyd D, Kumar R (2003) Prognostic significance of urokinase-type plasminogen activator receptor (uPAR) expression in prostate cancer. J Natl Cancer Inst 95: 1344–1349

McBride C, Corrie C, Capon C, Bernard D, Schmidt R (2003) Carbohydrate expression and modification during keratinocyte differentiation in normal human and reconstructed epidermis. Exp Dermatol 12: 537–545

Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kaminono S (1999) Elevation of serum levels of urokinase-type plasminogen activator receptor and its receptor: human breast epithelial cell invasion. Cancer Res 61: 400–405

Momburg F, Moldenhauer G, Hämmerling GJ, Möller P (1987) Immunohistochemical study of the expression of a Mr 34 000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res 47: 2883–2891

Montouru N, Visconte V, Rossi G, Rago P (2005) Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules? Thromb Haemost 93: 192–198

Nagy N, Legendre H, Engels O, Andre S, Kalter H, Wasano K, Zick Y, Pector JC, Decaestecker C, Gabius HJ, Salmon I, Kiss R (2003) Defining prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting. Cancer 97: 1849–1858

Nakamura M, Inufusa H, Adachi T, Aga M, Kurimoto M, Nakatani Y, Wakano T, Nakajima A, Hida JI, Miyake M, Shindo K, Yasutomi M (1999) Involvement of galectin-3 expression in colorectal cancer progression and metastasis. Int J Oncol 15: 141–148

Orntoft TF, Vestergaard EM (1999) Clinical aspects of altered glycosylation of glycoproteins in cancer. Electrophoresis 20: 362–371

Pappot H, Hoyer-Hansen G, Ronne E, Hansen HH, Brunner N, Dano K, Grondahl-Hansen J (1997) Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. Eur J Cancer 33: 867–872

Paret C, Bourouba M, Beer A, Miyazaki K, Schnöller M, Fiedler S, Zöller M (2005) Ly6 family member C4.4A binds laminins 1 and 5, associates with galectin-3 and supports cell migration. Int J Cancer 115: 724–733

Ploug M, Ellis V (1994) Structure–function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins. FEBS Lett 349: 163–168

Ploug M, Eriksen J, Plesner T, Hansen NE, Dano K (1992) A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria. Eur J Biochem 208: 397–404

Reisser D, Olsson NO, Martin F (1993) In vivo and in vitro reactivity of rat spleen cells against regressor and progressor colon-cancer cell variants. Int J Cancer 53: 651–656

Rösel M, Claas C, Seiter S, Herlevesen M, Zöller M (1998) Cloning and functional characterization of a new phosphatidyl-inositol anchored molecule of a metastasizing rat pancreatic tumor. Oncogene 17: 1989–1992

Schoepppner HL, Raz A, Ho SB, Bresalier RS (1995) Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer 75: 2818–2826

Seiter S, Stassar M, Rappel G, Reinhold U, Tilgen W, Zöller M (2001) Upregulation of C4.4A expression during progression of melanoma. J Invest Dermatol 116: 344–347

Sela BA, Stepelewski Z, Koprowski H (1989) Colon carcinoma-associated glycoproteins recognized by monoclonal antibodies CO-029 and GA22-2. Hybridoma 8: 481–491

Sidenius N, Andolfö A, Fesce R, Blasi F (2002) Urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization. J Biol Chem 277: 27982–27990

Sidenius N, Sier CF, Blasi F (2000) Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo. FEBS Lett 475: 52–56

Sier CF, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Dano K, Brunner N, Blasi F (1998) The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer 58: 1843–1849

Smith BA, Kennedy WJ, Harnden P, Selby PJ, Tredosiewicz LK, Southgate J (2001) Identification of genes involved in human urothelial cell–matrix interactions: implications for the progression pathways of malignant urothelium. Cancer Res 61: 1678–1685

Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sorensen S, Dano K, Brunner N (1999) Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 91: 869–874

Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJ, Hoyer-Hansen G, Ronne E, Dybkjær E, Dano K, Brunner N (1997) ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 43: 1868–1876

Taylor DD, Black PH (1986) Shedding of plasma membrane fragments. Neoplastic and developmental importance. Dev Biol 3: 33–57

Tsetlin V (1999) Snake venom alpha-neurotoxins and other ‘three-finger’ proteins. Eur J Biochem 264: 281–286

Tsetlin V, Witzal DT, Yao N, Drummond RJ, Rosenberg SA, Chapman HA (1994) Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269: 32380–32388

Wei Y, Witzal DT, Yao N, Drummond RJ, Rosenberg S, Chapman HA (1994) Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269: 32380–32388

Wilhelm OG, Wilhelm S, Escott GM, Lutz V, Magdolen V, Schmitt M, Ritkin DB, Wilson EL, Graeff H, Brunner G (1999) Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression. J Cell Physiol 180: 225–235

Würfel J, Seiter S, Stassar M, Claas A, Klas R, Rösel M, Marbach R, Savelieva L, Schwab M, Matzku S, Zöller M (2001) Cloning of the human homologue of the metastasis-associated rat C4.4A. Gene 262: 35–41

Zöller M, Matzku S, Goerttler K (1978) High incidence of spontaneous transplantable tumours in BD IX rats. Br J Cancer 37: 61–66